Trastuzumab Not Yet Recruiting Phase 2 Trials for HER2-Positive Early Breast Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03674112A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer